Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

Blood (2023) 142 (Supplement 1): 2848.

https://doi.org/10.1182/blood-2023-180733

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Blood (2023) 142 (Supplement 1): 6483.

https://doi.org/10.1182/blood-2023-186086

Published: 2023

Journal Articles

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Blood (2022) 140 (Supplement 1): 205–207.

https://doi.org/10.1182/blood-2022-166452

Published: 2022

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies

Blood (2021) 138 (Supplement 1): 309.

https://doi.org/10.1182/blood-2021-152548

Published: 2021

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-139847

Published: 2020

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Blood (2019) 134 (Supplement_1): 4158.

https://doi.org/10.1182/blood-2019-129751

Published: 2019

Journal Articles

Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Colombe Saillard, MD, Frederique Rousseau, Maud Cecile, Cecile Braticevic, Anne Etienne, Jerome Rey, Evelyne D'Incan, Christophe Zemmour, Norbert Vey, MD PhD, Aude Charbonnier

Blood (2018) 132 (Supplement 1): 2671.

https://doi.org/10.1182/blood-2018-99-116400

Published: 2018

Journal Articles

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

Norbert Vey, MD PhD, Marie Anne Hospital, Aude Collignon, Yves Collette, Daniel Birnbaum, Aude Charbonnier, Bilal Mohty, MD, Evelyne D'Incan, Jerome Rey, Remy Castellano, Camille Montersino, Max Chaffanet, Nadine Carbuccia, Jose Adelaide, Benjamin Bouchacourt, Arnaud Guille

Blood (2018) 132 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2018-99-119263

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients > 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis

Raynier Devillier, Jerome Rey, MD, Samia Harbi, MD, Aude Charbonnier, MD, Sabine Furst, MD, Colombe Saillard, MD, Angela Granata, MD, Evelyne D'Incan, MD, Catherine Faucher, MD, Claude Lemarie, Pharm.D., Faezeh Legrand, MD, Boris Calmels, Pharm.D., Valerio Maisano, MD, Bilal Mohty, MD, Christian Chabannon, MD PhD, Pierre Jean Weiller, MDPhD, Didier Blaise, Norbert Vey

Blood (2017) 130 (Supplement 1): 3327.

https://doi.org/10.1182/blood.V130.Suppl_1.3327.3327

Published: 2017

Journal Articles

Long-Term Survival of Patients with Chronic Phase Chronic Myeloid Leukemia Who Received Autologous Stem Cell Transplantation and Further Exposed to Tyrosine Kinase Inhibitors. a Study on Behalf of the French Society of Blood and Marrow Transplantation and the French Group of CML

Mauricette Michallet, MD PhD, Mohamad Sobh, Aude Charbonnier, MD, Eric Deconinck, MD PhD, Viviane Dubruille, MD, Valerie Coiteux, MD, Martine Delain, MD, Francoise Huguet, MD, Delphine Rea, MD, Dominique Bron, Nicole Raus, Data Manager, Alain Jacques Delmer, MD, Pascal Lenain, MD, Noel Milpied, Francois-Xavier Mahon, MD PhD, Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD

Blood (2017) 130 (Supplement 1): 4540.

https://doi.org/10.1182/blood.V130.Suppl_1.4540.4540

Published: 2017

Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Blood (2017) 130 (Supplement 1): 899.

https://doi.org/10.1182/blood.V130.Suppl_1.899.899

Published: 2017

Journal Articles

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Clemence Marcault, MD, Geoffroy Venton, Lauris Gastaud, MD, Lionel Mannone, MD, Jerome Rey, MD, Evelyne D'Incan, MD, Colombe Saillard, MD, Aude Charbonnier, MD, Sophie Raynaud, MD PhD, Norbert Vey, Thomas Cluzeau, MDPhD

Blood (2017) 130 (Supplement 1): 2615.

https://doi.org/10.1182/blood.V130.Suppl_1.2615.2615

Published: 2017

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison

Raynier Devillier, Sabine Furst, MD, Jerome Rey, MD, Angela Granata, MD, Aude Charbonnier, MD, Samia Harbi, MD, Evelyne D'Incan, MD, Thomas Pagliardini, Catherine Faucher, MD, Claude Lemarie, Pharm.D., Colombe Saillard, MD, Faezeh Legrand, MD, Boris Calmels, Pharm.D., Bilal Mohty, MD, Valerio Maisano, MD, Christian Chabannon, MD PhD, Pierre Jean Weiller, MDPhD, Norbert Vey, Didier Blaise

Blood (2017) 130 (Supplement 1): 2038.

https://doi.org/10.1182/blood.V130.Suppl_1.2038.2038

Published: 2017

NARROW

Poor Prognosis of SRSF2 Gene Mutations in Patients Treated with Venetoclax-Azacitidine (VEN-AZA) for Newly Diagnosed Acute Myeloid Leukemia. a Multicentric Real-Life Study of 117 Patients

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing ≥ 3 Prior TKI Therapies: Initial Safety and Efficacy

Evaluation of a Standardized Geriatric Assessment at Diagnosis in a Prospective Cohort of Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Patients > 60 Years with Acute Myeloid Leukemia in First Complete Remission: A 10-Year Single Center Transplantation Program Analysis

Long-Term Survival of Patients with Chronic Phase Chronic Myeloid Leukemia Who Received Autologous Stem Cell Transplantation and Further Exposed to Tyrosine Kinase Inhibitors. a Study on Behalf of the French Society of Blood and Marrow Transplantation and the French Group of CML

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Topotecan Plus Cytarabine Is an Effective and Safe Regimen for Newly Diagnosed and Adverse ELN-Risk Acute Myeloid Leukemia Subset in Patients with Cardiac Comorbidities

Allogeneic Hematopoietic Stem Cell Transplantation for Patients over 60 Years with Acute Myeloid Leukemia: A Single Center Donor Comparison

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only